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ABSTRACT
Prediction of Response to Escitalopram Across Multiple Outcomes in Older Adult GAD
Patients
Caroline M. Ciliberti
Anxiety disorders are common in late-life and have detrimental effects of health and
well-being (Stanley, Diefenbach, & Hopko, 2003; Wetherell et al., 2004). Generalized
Anxiety Disorder (GAD) is the most common anxiety disorder in late-life (Beekman et
al., 1998). Beyond the diagnostic symptoms, older adults with anxiety disorders may
present with a variety of physical symptoms (Palmer, Jeste, & Sheikh, 1997). As a result,
GAD is a heterogeneous disorder. Empirically-supported treatments are available for latelife GAD, but little is known about how people with different constellations of presenting
symptoms respond to treatment, and whether they differ according to the way in which
improvement is measured. The present study aimed to identify which presenting
symptoms differentiated older adults with GAD from those without and how those
symptoms predicted outcome across several domains of response. Participants were
enrolled in a trial testing the efficacy of escitalopram for treatment of late-life GAD. One
hundred and seventy-seven older adults with GAD and 41 older adults with no diagnosis
participated. One hundred percent of the cases were correctly classified on the basis of
the ―Anxious Mood‖ and ―Tension‖ SIGH-A items. A subset of participants with GAD
who had been randomly assigned to received escitalopram and had completed 12 weeks
of blinded treatment were further analyzed. Neither ―Anxious Mood‖ nor ―Tension‖
significantly predicted outcome in any domain. However, baseline scores on several of
the outcome measures accounted for a significant amount of variance in week 12 scores,
with lower scores being associated with better outcomes. These results indicate that
baseline scores are the best predictors of outcome, and could have implications for
treatment of GAD in late-life.
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Prediction of Response to Escitalopram Across Multiple Outcomesin Older Adult GAD Patients
Anxiety Disorders are common in late life, affecting 10.2% of older adults (Beekman et
al., 1998). Despite their prevalence, anxiety disorders are often under-identified and underdiagnosed among older adults (Harman, Rollman, Hanusa, Lenze, & Shear, 2002). There are
several challenges to detecting and diagnosing anxiety disorders among older adults that may
account for this. Most screening instruments were developed for use with younger adults and
may be inappropriate for use with older adults. Older adults may differ from younger adults in
how they report their symptoms. Specifically, older adults are more likely to underreport
symptoms of psychological distress (Tweed, Blazer, & Ciarlo, 1992), and may report different
symptoms than younger adults, and are less likely than younger adults to report worthlessness
associated with anxiety (Shapiro, Roberts, & Beck, 1999). Further, older adults tend to be more
exact when describing negative affective states (Shapiro et al., 1999), emphasizing the
importance of capturing the lexicon of older adults when screening for anxiety disorders.
There are conflicting findings about somatic presentations of anxiety in older adults. For
example, Christensen and colleagues (1999) found that older adults reported fewer somatic
symptoms of anxiety on assessment instruments, such as headaches and physical tension, in
comparison to younger adults. In contrast, some studies have found that older adults report more
somatic symptoms than younger adults (Spar & LaRue, 1990), and still others have found no
difference in the reporting of somatic symptoms between age groups (Stanley et al., 2003).
Further complicating diagnosis, anxiety disorders frequently are comorbid with another
Axis I disorder, or a physical disorder among older adults. Perhaps due in part to an overlap in
diagnostic symptoms, 27.5% of older adults diagnosed with major depression are also diagnosed
with an anxiety disorder (Lenze et al., 2000). People with anxiety disorders also have more
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physical comorbities, and greater physical disability than those without (Brenes et al., 2005; de
Buers et al., 1999; Palmer, Jeste, & Sheikh, 1997). Palmer and colleagues (1997) outline several
possible factors that may explain this co-occurrence. First, both physical illness and anxiety are
common in older adults, and thus co-occur. Second, some symptoms of anxiety are somatic. For
example, palpitations and sweating may be manifestations of anxiety but are sometimes
interpreted as signs of physical illness. It is also the case that anxiety might result from the stress
of having a physical illness. Finally, some physical illnesses (e.g., hyperthyroidism) may present
as anxiety, and some medications used to treat physical illnesses may cause anxiety as a side
effect (Palmer et al., 1997). These factors make detecting anxiety in older adults challenging.
As a result of these age-related differences in the experience and presentation of anxiety
symptoms, the current diagnostic criteria may not adequately capture the experience and
presentation of anxiety in older adults, leading to under-recognition. Thus, older adults may go
undiagnosed with anxiety symptoms, resulting in a lifestyle associated with diminished well
being, increased use of health services, more severe depression, and poorer social functioning (de
Buers et al., 1999; Lenze et al., 2001).
Of the anxiety disorders, Generalized Anxiety Disorder (GAD) is the most common
among older adults, affecting 7.3% of community dwelling older adults (Beekman et al., 1998).
GAD is associated with poorer quality of life (Bourland et al., 2000; Porensky et al., 2009;
Stanley, Diefenbach, & Hopko, 2003; Wetherell et al., 2004), and worse perceptions of mental
and physical health (Stanley et al., 2003) than of individuals without this disorder. According to
the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV; APA, 1994)
criteria, GAD is characterized by excessive and difficult to control worry about multiple events,
occurring on most days for a minimum of 6 months. The worry is accompanied by three or more
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of the following six symptoms: restlessness or feeling edgy, being easily fatigued, trouble
concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. However,
the proposed criteria for the 5th edition of the DSM focus more on distress and impairment due to
worry, requiring excessive and interfering worry and either restlessness or muscle tension to
receive a diagnosis of GAD (APA, 2010). These proposed changes put more emphasis on the
core symptom of GAD: worry. Many people with GAD expend a disproportionate amount of
time worrying about everyday situations, and find it difficult to stop worrying. In addition to the
diagnostic symptoms, some people with GAD experience an increase in somatic symptoms, such
as upset stomach and sweating (APA, 1994). Though some worries (e.g., worries about family,
and health of a loved one) seem to be common among all older adults, certain topics of worry
have been shown to differentiate older adults with GAD from those without GAD (Wetherell, Le
Roux, & Gatz, 2003). These topics include worry about small matters, finances, personal health,
and social matters (Wetherell et al., 2003). However, only 13.3% of patients with GAD present
for treatment with anxiety as their primary complaint (Wittchen et al., 2002). Instead, many
present with physical symptoms (Flint, 2005; Wittchen et al., 2002). Because of the complicated
nature of the link between somatic symptoms and anxiety in older adults, it is often difficult for
providers to determine whether these presenting somatic symptoms are actual symptoms of GAD
or a result of some physical illness. Wetherell and colleagues (2003) examined the associated
diagnostic symptoms among older adults with GAD and older adults with no DSM diagnosis.
Older adults with GAD were more likely than members of the control group to endorse trouble
sleeping, muscle tension, fatigue, restlessness, and irritability. Sleep disturbance and muscle
tension are especially salient among older adults with GAD. However, trouble concentrating did
not distinguish those with GAD from the control group (Wetherell et al., 2003). Beck, Stanley,
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and Zebb (1999) also compared older adults with GAD to older adults with no DSM diagnosis.
They found older adults with GAD differed in regard to categories of self-reported symptoms
(i.e., tension and anxiety, somatic symptoms, and agitated behavior).
In addition to the diagnostic and presenting symptoms of GAD discussed above,
neurobiological markers have been proposed for the identification of GAD. Some hypothesize
that depression and anxiety are characterized by hypothalamic pituitary adrenal (HPA) axis
dysregulation in the brain, resulting in abnormal levels of the stress hormone, cortisol (Mantella
et al., 2008). Researchers can make inferences about HPA-axis functioning by measuring the
production of cortisol. Researchers often measure salivary cortisol levels because it is a
minimally invasive technique, and levels of salivary cortisol correspond with levels of serum
cortisol (Hansen, Garde, & Persson, 2008). It is important to examine the neurobiology of older
adults because it is possible that there are significant changes with age. Studies of HPA axis
activity in older adults have shown increases in activity associated with increased age (Van
Caurter et al., 1996), and increases in mean levels of cortisol (Ferrari, Magri, Dori, Migliorati,
Nescis, Molla, Fioravanti, & Solerte, 1995). There is also evidence that HPA axis dysregulation
may be linked to anxiety disorders in older adults. More severe GAD, as measured by the Penn
State Worry Questionnaire (PSWQ) and the GAD Severity Scale (GADSS; Shear, Belnap,
Mazumdar, Houck, & Rollman, 2006), has been shown to be associated with higher levels of
salivary cortisol (Mantella et al., 2008). Further, older adults with anxiety disorders show higher
levels of cortisol after being exposed to stressors than older adults without anxiety disorders
(Chaudieu et al., 2008). Chronic exposure to stress hormones may result in a host of negative
outcomes, including impaired immune functioning and more cardiovascular stress. Such
exposure also may contribute to the development of dementia (Mantella et al., 2008).
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When appropriately identified, there are several pharmacological and psychosocial evidencebased treatments available to older adults with GAD.

Historically, benzodiazepines were used

to treat anxiety in older adults, but because of significant risks, most prescribers have moved
towards the use of antidepressants as a first line treatment of GAD (Sheikh & Cassidy, 2000).
The antidepressants venlafaxine ER and citalopram have been shown to be effective for treating
GAD in older adults, resulting in improved clinical global impressions and improved Structured
Interview Guide for the Hamilton Anxiety Scale (SIGH-A ; Shear et al., 2001) scores (Katz et al.,
2002; Lenze et al., 2005). Escitalopram also has been shown to be effective for treating GAD,
resulting in improvement in clinical global impressions, lower levels of worry (as measured by
the PSWQ) and improved quality of life (as measured by the Short Form -36) (SF-36; Ware &
Sherbourne, 1992). Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that has been
shown to be an effective treatment for GAD (Goodman, Bose, & Wang, 2005; Lenze, et al.,
2009). In a pooled analysis of randomized controlled trials examining the efficacy of
escitalopram in participants ranging from 18 to 80, escitalopram was shown to be well tolerated
and effective at reducing post treatment Hamilton Anxiety Rating Scale scores (Goodman, Bose,
& Wang, 2005). Several psychosocial treatments also have been shown to be efficacious among
older adults with GAD. Relaxation training and cognitive-behavior therapy (CBT) have the most
support for their efficacy in the treatment of GAD among older adults (Ayers, Sorrell, Thorp, &
Wetherell, 2007). A review by Ayers and colleagues (2007) found 9 studies supporting the use of
CBT for treatment of GAD in older adults. For example, Mohlman et al. (2003) found that older
adults with GAD receiving CBT showed a greater reduction in GAD severity at 6 months follow
up than those in a wait-list control group. Stanley, Beck, and Glassco (1996) found that CBT
treatment resulted in reduced anxiety, worry, and depression, as measured by GAD severity, the
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PSWQ, the Hamilton Anxiety Scale, the Worry Scale (WS; Wisocki, Handen, & Morse, 1986),
and the State Trait Anxiety Inventory – Trait (STAI-T; Spielberger, Gorsuch, & Lushene, 1970).
Several of the studies discussed above used different strategies for measuring treatment
response (e.g., a drop in scores on a measure of anxiety, a global rating of improvement, or a
change in quality of life measures) and consequently used different definitions of response to
determine whether an intervention was effective. These outcome measures are certainly helpful,
but they may not adequately depict response to treatment.
Most of the research studies supporting both pharmacological and psychosocial
treatments of GAD have measured improvement by examining changes in total scores on
assessment instruments. Few studies have performed a fine grained analysis of the qualitative
changes in individual anxiety symptoms with treatment. Lecrubier, Dolberg, Anderson, and
Weiller (2008) examined qualitative changes in symptomatology with escitalopram treatment, by
examining patterns of treatment changes in people with GAD, Major Depressive Disorder
(MDD), and patients with mixed anxiety and depression. Their work focused largely on
describing treatment effects by retrospectively examining the specific groups of symptoms that
changed with treatment. Stein, Anderson, and Goodman (2005) pooled 3 antidepressant
treatment studies, and examined changes in the symptom clusters assessed on the SIGH-A
among adults with GAD. They found significant treatment effects for 7 of the 14 symptom
clusters (anxious mood, tension, fears, insomnia, intellectual, depressed mood, and interview
behavior). Though both the Lecrubier and the Stein studies took a closer look at the specific
qualitative changes of anxiety symptoms with treatment, neither study focused on older adults
with GAD.
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In addition to examining changes with treatment, researchers have attempted to identify
pre-treatment variables that predict outcome (See Tables 1 and 2 for summaries). The ability to
predict outcome based on pre treatment presentation may help providers make informed
treatment decisions when planning patient care. Predictors of treatment response have been
explored for both psychosocial and pharmacological therapies for the treatment of a variety of
anxiety disorders (e.g., panic disorder and GAD). Some diagnostic symptoms (e.g., sleep
disturbance) have also been shown to predict positive response to treatment, while others (e.g.,
restlessness) predict poorer outcomes (Pollack, Meoni, Otto, & Hackett, 2003). A history of
substance abuse has been shown to predict positive outcomes (Pollack et al., 2003), while recent
benzodiazepine use has been shown to predict negative outcomes (DeMartinis, Rynn, Rickels, &
Mandos, 2000). Further, early improvement has been shown to be associated with better longer
term outcomes (Rynn et al., 2006). Older age has been shown to predict poorer treatment
outcomes, as have certain baseline comorbidities, including the presence of a personality
disorder (Seivewright, Tyrer, & Johnson, 1998). Haby, Donnelly, Corry, and Vos (2006) found
that treatment studies that included samples with greater severity had poorer outcomes than those
that didn’t. Other study-design variables, including waitlist control, were associated with poorer
outcomes. Durham, Allan, and Hackett (1997) found that being married was associated with
more favorable outcomes, whereas marital stress was associated with poorer outcomes. Further,
comorbid diagnoses were also associated with poorer outcomes.
Only one study has examined the factors that predict GAD treatment response in a sample
of older adults. Wetherell and colleagues (2005) pooled data from 3 psychotherapy treatment
studies for older adults. Outcome was measured using a Reliable Change Index, or RCI, for
three measures: the GAD severity rating, Hamilton Anxiety Rating Scale (HAM-A), and PSWQ.
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The RCI is an outcome measure used to quantify treatment gains. Better outcomes were
associated with higher GAD severity at baseline, presence of Axis I comorbidity, and more
frequent homework (Wetherell et al., 2005).
In sum, several studies have examined demographic, psychiatric, and treatment variables
that predict treatment response for GAD. However, only one (Wetherell et al., 2005) has used a
sample of older adults, and only one (Pollack et al., 2003) has examined the predictive value of
the different symptom presentations. There have been no studies that have examined the
predictive value of common symptom presentations of anxiety, beyond those outlined by the
DSM, and none that have examined the predictive value of symptom presentations in older
adults. It is possible that the DSM does not adequately capture the experience of anxiety in older
adults, considering the diagnostic challenges discussed above. Moreover, the DSM diagnostic
symptoms are broad and vaguely worded (Brown & Barlow, 2009). The threshold levels used to
diagnose GAD are not based on empirical evidence, and are difficult to assess in clinical practice
(Brown & Barlow, 2009). Considering the unique presentations of anxiety in older adults,
knowledge of how symptoms predict positive treatment outcome would be valuable.
Treatment outcome researchers have defined response in different ways. Some studies
have relied on global measures of improvement, some on reduction in worry, and some on
changes in physiological responses. However, it is unclear how these response measures relate
to each other, and how the course of treatment may differ according to how one defines response.
Typically, researchers rely on one outcome measure, assessing one response mode, to determine
the efficacy of an intervention. Treatment studies of GAD frequently focus on either change
scores on a single measure of anxiety (e.g., SIGH-A, HAMA, PSWQ), or measures of global
improvement (e.g., CGI). However, some researchers (e.g., Barlow, 1981) have proposed that
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statistically significant outcome measures typically used in research settings may have little
practical significance for the patients. Moreover, some have noted that there is a rift between
research outcomes and clinically relevant patient care (Tunis, Stryer, & Clancy, 2003). There
may be little concordance between standard clinical measures, and clinically relevant
improvement (Glasgow, Magid, Beck, Ritzwoller, & Estabrooks, 2005).
In addition to measures of symptom severity, some advocate for collecting a broad range
of outcome measures to determine the clinical relevance of a treatment. Some authors have
called for a ―patient-centered approach,‖ that relies on practical and relevant outcome measures
such as quality of life, functional outcome, and satisfaction (Glasgow et al., 2005; Tunis et al.,
2003). The importance of examining multiple response modes, including motoric, cognitive, and
physiological responses, has also been stressed for decades in the assessment literature (Eid &
Diener, 2006; Hayes and O’Brien, 2000; Lang, 1968). This is important, in part, because of the
discordance between response modes, which is especially salient in anxiety disorders (e.g., Glass
& Arnkoff, 1989; Lang, 1968). For example, a person’s cognitive response to a feared stimulus
(e.g., ―I feel scared.‖) may not necessarily match his or her physiological response (e.g.,
increased levels of salivary cortisol, increased blood pressure). Similarly, self-reported fear may
not match a person’s actions or physiological response. Such findings also suggest variability in
patterns of response to arousing stimuli across individuals (Lacey, Bateman, & Van Lehn, 1953).
Thus, some outcome measures will more accurately reflect an individual’s response to arousing
stimuli than others. In summary, these findings reinforce the importance of examining treatment
outcome comprehensively, and certainly beyond the usual measures of anxiety or global
improvement in older adults.
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Statement of the Problem
Anxiety disorders are common among older adults, affecting up to 10.2% of older adults
(Beekman et al., 1998). Generalized Anxiety Disorder (GAD) is the most common of the
anxiety disorders among older adults, affecting 7.3% of those in the community (Beekman et al.,
1998). However, GAD often goes underreported and undertreated in older adults (Harman et al.,
2002), in part because of some unique challenges to diagnosis in this population (Lenze et al.,
2000; Palmer et al., 1997). For example, older adults may present with different symptoms than
younger adults (Christensen et al., 1999; Shapiro et al., 1999; Spar & LaRue,1990). Further,
frequent medical and psychiatric comorbidities may complicate the diagnostic picture due to
overlap in symptoms (Lenze et al., 2000; Palmer et al., 1997). This under-detection is
problematic because GAD is associated with poorer quality of life (Bourland et al., 2000;
Porensky et al., 2009; Stanley et al., 200; Wetherell et al., 2004;), and worse perceptions of
mental and physical health (Stanley et al., 2003) among older adults. Moreover, GAD may be
associated with abnormal HPA-axis functioning, and thus elevated levels of cortisol, which may
put older adults with GAD at risk for more health problems, including dementia (Beaudreau, S.
& O’Hara, R., 2008; Chaudieu et al., 2008; Mantella et al., 2008; Van Cauter et al., 1996).
Researchers have attempted to identify potential predictors of treatment outcome,
including demographic, psychiatric, and treatment variables (See Tables 1 and 2 for a summary).
The identification of patient variables that can predict treatment outcome in older adults with
GAD could have significant clinical and research implications. For example, knowledge of
symptom presentations that predict positive treatment outcomes with particular treatments could
guide providers when making treatment choices.
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Because older adults may present with different symptoms of anxiety than younger adults
(Christensen et al., 1999; Shapiro et al., 1999; Spar & LaRue,1990), the symptoms that predict
treatment success for them may also differ from those that predict success in younger adults.
Only one study has examined the predictive value of baseline symptoms and treatment variables
for treatment outcome in a sample of older adults. Using a Reliable Change Index, or RCI, for
three measures (GAD severity rating using Anxiety Disorders Interview Schedule for Adults
(ADIS-IV; Brown, DiNardo, & Barlow, 1994) ratings, HAMA scores, and PSWQ scores),
Wetherell and colleagues found that better outcomes were associated with higher GAD severity
at baseline, presence of Axis I comorbidity, and more frequent homework (Wetherell et al.,
2005). However, this study relied on total scores from their clinical measures and various
treatment variables, rather than specific presenting symptoms, to predict outcome. Although
helpful, such studies do not provide a fine-grained analysis of the presenting symptoms that are
associated with positive outcomes.
Because older adults may present with different symptoms of anxiety than their younger
counterparts (Christensen et al., 1999; Shapiro et al., 1999) it may be useful to take a broader
look at the symptoms that predict response, beyond the DSM criteria. For example, no studies
have examined the predictive value of somatic manifestations of anxiety (e.g., cardiovascular
symptoms and gastrointestinal distress) on treatment outcome.
For those older adults whose anxiety disorders are identified, effective pharmacological
(Lenze et al., 2009; Sheikh & Cassidy, 2000) and psychosocial (see Ayers et al., 2007 for a
review) treatments are available. Though there have been several promising treatment studies,
both examining pharmacological and psychosocial treatments, there is no consistently used
treatment outcome measure and no consensus on what outcome measure should be used. Some
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of the studies discussed above defined treatment outcome as a reduction of worry (e.g., Stanley
et al., 1996), while others defined response as a reduction in presenting symptoms of anxiety
(e.g., Lenze et al., 2005). Still others defined response as reduction in GAD severity (e.g.,
Mohlman et al., 2003), improved quality of life (e.g., Lenze et al., 2009; Stanley et al., 1996), or
overall global improvement (e.g., Lenze et al., 2009). Most studies examined some combination
of these response measures, but focused outcome on one measure of response. In addition to
traditional outcome measures of symptom severity and morbidity, some have advocated the use
of multiple measures of outcome across different domains (Lang, 1968), and the use of measures
that have practical clinical significance (e.g., Glasgow et al., 2005; Tunis et al., 2003). Little
research has examined the ways in which treatment response varies according to how outcome is
measured, and whether a positive outcome in one domain is associated with a positive outcome
in others (e.g., is a reduction in worry associated with an improvement in quality of life?). It is
possible the people with different constellations of presenting symptoms respond to treatment in
different ways. However, most researchers haven’t specifically identified who improves from
what treatment, and in which ways they benefit.
In sum, researchers have identified predictors of treatment response among younger
adults. However, only one study has examined predictors in older adults (Wetherell et al., 2005),
and only one study has examined the predictive power of specific symptom presentations,
beyond DSM criteria, in a sample of young adults (Pollack et al., 2003). We lack a clear picture
of the value of the manifestations of anxiety, beyond the symptoms represented by the DSM-IV
criteria, for predicting treatment response with older adults. Moreover, the value of these
predictors appears to vary depending upon how researchers have defined treatment response in
each of the outcome studies. It is possible that the course of treatment, and treatment
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effectiveness may vary according to how response is measured. Previous studies typically have
not employed outcome measures that examine change across different response modes.
The present study was designed to address two objectives. The first objective was to
identify presenting symptoms that differentiate older adults with GAD from those without GAD.
The second objective was to determine which of those symptoms were predictive of treatment
response, and how the symptoms predicted response for each of several different outcome
measures. To address the first objective, the current study examined the value of baseline levels
of common presenting symptoms of GAD, as measured by SIGH-A items, in their ability to
discriminate older adults with GAD from older adults without GAD. Using the baseline levels of
the symptoms that differentiated older adults with GAD from those without, the current study
addressed the second objective by examining the ability of these symptoms to predict treatment
outcome in a sample of older adults with GAD receiving escitalopram. The SIGH-A is
comprised of 14 clusters of common presenting symptoms (anxious mood, tension, fears,
insomnia, concentration, depressed mood, somatic muscular, somatic sensory, cardiovascular,
respiratory, gastro-intestinal, genitor-urinary, autonomic, and behavior). The current study
examined the extent to which the baseline levels of symptom clusters that differentiated
individuals with GAD from those without predicted successful treatment outcome as measured
by the PSWQ scores, SF-36 quality of life scores (Mental and Physical components), global
improvement scores, and cortisol levels.

Method
Participants
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One hundred and seventy-seven participants, aged 60 and older, were recruited between the years
2004 and 2008 for the parent study: a double-blind placebo controlled medication treatment
study of the efficacy of escitalopram for the treatment of generalized anxiety disorder in older
adults at the University of Pittsburgh Medical Center (Lenze et al., 2009). Participants were
recruited from primary care clinics, specialty medical care clinics, mental health clinics, and
community advertisement. Most of the participants were Caucasian (82%), and female (67.2%).
Nearly one-quarter (24.8%) of the participants had a current diagnosis of a depressive disorder,
and 20.9% had a diagnosis of a comorbid anxiety disorder, other than GAD. All participants
received one hundred dollars and study medication at no cost.
Each participant was assessed using the Structured Clinical Interview for DSM Disorders
(SCID; First, Spitzer, Gibbon, & Williams, 2002), and met criteria for a principal diagnosis of
GAD, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV; APA, 1994). Each participant scored 17 or higher on the SIGH-A, indicating
clinically significant levels of anxiety. Participants with active suicidal ideation, drug or alcohol
abuse or dependence in the previous 6 months, a lifetime prevalence of psychosis or bipolar
disorder, dementia, medical instability, or current psychotherapy, antidepressant, or anxiolytic
treatment were excluded from the study (Lenze et al., 2009).
To examine variables that predict treatment response to escitalopram, a subset of
participants was examined. Of the 177 participants who were randomized into the parent study,
70 participants were randomized to escitalopram and completed 12 weeks of blinded treatment.
Because researchers for the parent study did not begin collecting salivary cortisol samples at the
outset of the study, salivary cortisol data are not available for some participants. Of those 70
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participants who were randomized to escitalopram and completed 12 weeks of treatment, only 23
collected both baseline and week 12 samples of salivary cortisol.
Forty-one control participants were also recruited. Control participants had no SCID
diagnosis. As with participants in the active group, control participants with active suicidal
ideation, a lifetime prevalence of dementia, medical instability, or current psychotherapy,
antidepressant, or anxiolytic treatment were excluded from the study.
Materials
Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A; Shear et al.,
2001). The Structured Interview Guide for the Hamilton Anxiety Rating Scale, or SIGH-A, is a
14-item structured interview based on the Hamilton Rating Scale (HAMA; Hamilton, 1959) that
is used to measure anxiety (See Appendix A). The items cover a range of psychological,
physiological, and behavioral manifestations of anxiety. Each item is rated on a scale from 0 to
4, with higher scores indicating increased duration, distress, and impairment. The HAMA is
widely used to assess anxiety and has been validated for use with older adults (Beck, Stanley, &
Zebb, 1999). The HAMA has been shown to demonstrate good internal consistency (α = .77)
among participants with GAD (Beck et al., 1999). Further, it had good discriminant validity,
correctly classifying 98% of older adults with GAD, and 100% of older adult controls (Beck et
al., 1999). The SIGH-A was developed by Shear and colleagues (2001) from the HAMA. The
SIGH-A offers more detailed instructions for administration, and clearer anchor points for rating.
Though not tested in older adults, the SIGH-A demonstrates good internal consistency when
tested over two days in a sample of adults with GAD (α = .79; Shear et al., 2001). SIGH-A
scores were also correlated with HAMA scores in a sample of adults aged 18 and older with
GAD (r= 0.70 on day one, r= 0.72 on day two) (Shear et al., 2001). The SIGH-A is organized
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into 14 clusters of symptoms: anxious mood, tension, fears, insomnia, concentration, depressed
mood, somatic muscular, somatic sensory, cardiovascular, respiratory, gastro-intestinal, genitorurinary, autonomic, and behavior.

Each cluster has a structured list of questions about various

symptoms that fall under the broader category of the cluster. The interviewer inquires about the
presence of each symptom, then rates the whole cluster on a scale from 0-4 based on the
frequency and severity of the collection of symptoms (See Appendix A). The current study
recorded the ―yes/ no‖ dichotomous response to each symptom under each category, to be able to
have a more detailed picture of the experience of anxiety in older adults.
Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990). The PSWQ is a 16-item
self-report questionnaire used to assess worry (See Appendix B). Each item is rated on a scale
from 1 (not at all typical) to 5 (very typical). Higher scores indicate higher levels of worry. In a
sample of older adults, moderate correlations were observed between the PSWQ and other
measures of anxiety, including the Worry Scale (WS; r=.54, p<.01), the original Fear
Questionnaire (FQ-A; r= .36), and the modified Fear Questionnaire (FQ-F; r=.30. , supporting
convergent validity (Stanley, Novy, Bourland, Beck, & Averill, 2001). Test-retest reliability of
the PSWQ among older adults has been shown to be moderate (r = .54; Stanley et al., 2001).
Short Form 36 Health Survey Questionnaire (SF-36; Ware & Sherbourne, 1992). The
SF-36 is a 36-item self-report measure of health that measures health across 8 dimensions:
physical functioning, social functioning, role limitations, mental health, vitality, pain, general
health perception, and health change (see Appendix C). High scores indicate better healthrelated quality of life and functioning. The SF-36 demonstrated good adequate internal
consistency on each of the 8 dimensions. SF-36 scores can be divided into two subscales. One
is referred to as the ―mental component‖ (SF-36 MC) and the other is referred to as the ―physical
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component‖ (SF-36 PC). Cronbach’s α ranged from .73 (social functioning) to .96 (role
limitations and vitality) (Brazier et al., 1992).
Clinical Global Impression- Improvement scale (CGI-I; Guy, 1976). The CGI-I is a
commonly used single item index used to quantify improvement or worsening of anxiety
symptoms since baseline (See Appendix D). Participants are rated on a scale from 1 to 7, where
1= very much improved, and 7= very much worse, based on a synthesis of patient’s subjective
report of improvement, change in measures, and clinician’s report. In a study of the clinical
utility of CGI-I scores for evaluating psychiatric in-patients with a wide range of diagnoses,
investigators found CGI-I scores were found to be correlated with other measures of clinical
change (r=.71), indicating clinical utility and sensitivity to change (Berk et al., 2008). Zaider,
Heimberg, Fresco, Schneier, and Lebowitz (2003) also found evidence supporting the validity of
the CGI-I as a meaningful measure of improvement in a sample of adults receiving treatment for
social anxiety. Zaider and colleagues (2003) found CGI-I scores to be correlated with both selfreport and clinician rated measures of social anxiety, disability, and quality of life at post
treatment.
Salivary Cortisol- Baseline samples of salivary cortisol were taken 6 times a day over 2
days before participants entered treatment because cortisol levels fluctuate throughout the day.
Follow up samples were taken 6 times a day over the 2 days before participants’ week 12 visits.
Samples were taken immediately at wakening, 30 minutes after wakening, noon, 3:00 pm, 6:00
pm, and before bedtime. Participants were instructed to not eat or drink anything other than
water for half an hour before taking a sample and to refrain from drinking alcohol for two days
prior to taking samples, and during the sampling period. Participants tracked the exact time at
which they took each sample on a diary form. Samples were stored at -80 C until they
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centrifugation. Samples were centrifuged using an enzyme immunoassay kit (Salimetrics, State
College, PA). Cortisol levels and diurnal cycles were plotted. Numerous studies have indicated
that cortisol may be a biomarker for psychological distress in older adults (Luz et al., 2003; Ryff
et al., 2006; Mantella et al., 2008).
Procedure
After participants were screened, those who were eligible were invited back for a baseline
visit. Two days prior to the baseline visit, participants collected samples of salivary cortisol. At
the baseline visit, participants completed measures of anxiety (the Structured Interview Guide for
the Hamilton Anxiety Rating Scale; SIGH-A), worry (the Penn State Worry Questionnaire;
PSWQ), and quality of life (the Short Form 36; SF-36) as part of a more extensive battery.
Participants were randomly assigned to either a starting dose of 10 mg of escitalopram, or a
placebo.
Both participants and investigators were blinded to this assignment. Participants received
weekly follow up assessments for the first 4 weeks, when they received another SIGH-A, a
measurement of side-effects, and a rating of global improvement, based on both clinician and
participant impressions of change since baseline. After 4 weeks, participants were eligible to
receive an increased dose of escitalopram (20 mg). All participants were eligible for a titrated
dose, unless they received a CGI score of ―much improved‖ or higher, and a 40% or greater drop
in SIGH-A score from baseline. Between week 4 and week 12, participants were assessed either
in person or by phone every 2 weeks.
After 12 weeks, participants ended the blinded phase of the study, and were offered open
label escitalopram for another 12 weeks. For two days before the week 12 visit, participants
collected follow up samples of salivary cortisol. At the week 12 visit, participants completed
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follow up measures, including the SIGH-A, PSWQ, and SF-36, as part of a more extensive
assessment battery. The current study examined data at baseline and week 12 in order to see how
baseline variables predict change after a sufficient course of medication.

Results
Descriptive statistics were calculated for the demographic data from the group with a
primary diagnosis of GAD and control participants (see Table 3). Descriptive statistics were also
calculated for both participants with GAD and those without fir baseline levels of the outcome
variables: PSWQ, SF-36 (mental and physical components), and salivary cortisol (see Table 4).
Salivary cortisol levels were reported as an area under the curve value, and were calculated using
the technique established in the literature (Mantella et al., 2008; Pruessner et al., 1997). Skew
and kurtosis were within one standard score from zero for all outcome variables with the
exception of the MOS-Physical Component, which had a z-score for kurtosis of -1.105. The data
were not transformed. For participants with GAD who were randomized to medication, paired
sample t-tests were conducted to determine whether the outcome variables differed significantly
at week 12 from baseline (See Table 5).
Baseline scores were significantly positively correlated with week 12 scores for the
PSWQ, r(68) = .80, p < .001; the SF-36 MC, r(68) = .52, p < .001; and the SF-36 PC, r(68) =
.79, p < .001(See Table 6). However, these scores are not independent. There were no
significant correlations between baseline AUC levels of salivary cortisol or week 12 AUC levels
and any other outcome variables. Because the CGI-I score assesses improvement from baseline,
no baseline CGI-I scores were collected. PSWQ week 12 scores were significantly correlated
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with all outcome measures, with the exception of salivary cortisol. Neither baseline nor week 12
levels of salivary cortisol were correlated with any other outcome variable.
A series of exploratory t-tests were performed to examine differences between the total
group of those with a primary diagnosis of GAD (n=177) and the control group on the 14
individual cluster scores of the SIGH-A measures. All items differed significantly between the
two groups (see Table 78).
Hypothesis Testing
The first objective was to determine which SIGH-A cluster symptoms were best at
differentiating older adults with GAD from those without GAD. To test this objective, a
discriminant function analysis was performed to determine which cluster item baseline scores
classified participants according to group membership. Baseline scores on each of the 14
symptom clusters of the SIGH-A were entered into the equation, The discriminant analysis
revealed one discriminant function, which included the ―Anxious Mood‖ and ―Tension‖ items
from the SIGH-A, and correctly classified 100% of the participants as either ―GAD‖ or ―no
GAD‖ (See Table 8), canonical R2 = .95 (λ = 0.1, χ2(2), p<.01) .
A correlation matrix was constructed to examine the relations between the predictor
variables (―Anxious Mood‖ and ―Tension‖ items) and baseline and week 12 scores on each of
the outcome measures: PSWQ, SF-36 MC, SF-36 PC, CGI-I, and AUC of salivary cortisol (see
Table 6). The ―Anxious Mood‖ item was significantly correlated with PSWQ scores at both
baseline, r(68) = .32, p < .001, and week 12, r(68) = .24, p < .01, and it was inversely correlated
with MOS MC scores at week 12, r(68) = -.24, p < .01.
The second objective was to determine how well the variables that best discriminate
between older adults with GAD and those without GAD predict improvement across a variety of

21
measures. To test the second objective, the ―Anxious Mood‖ and ―Tension‖ items were retained
for use in a linear regression to predict which symptom presentations predicted response across
outcome measures assessing different domains of treatment response (see Table 9). Five
hierarchical regression analyses with forward variable entry were completed, using different
outcome measures as the dependent variable for each analysis: worry level (as measured by the
change in PSWQ score from baseline to week 12 of treatment), quality of life (as measured by
the SF-36 Mental and Physical components change in from baseline to week 12 of treatment),
clinical global improvement (as measured by the CGI-I), and salivary cortisol levels (as
measured by change in salivary cortisol levels from baseline to week 12). To account for
baseline symptoms, baseline scores of the PSWQ, the SF-36 MC and PC, and salivary cortisol
were entered into the first step of their respective regression analyses. Baseline ―Anxious Mood‖
and ―Tension‖ SIGH-A item scores were added in the second step, using the backward entry
method. Because the CGI-I measures change from baseline, it was not necessary to account for
baseline scores when examining the predictive value of the SIGH-A items on week 12 CGI-I
score. To perform a regression analysis for CGI-I, both the ―Anxious Mood‖ and ―Tension‖
items were added to the model using backwards entry.
Two models were shown to predict week 12 PSWQ scores proved to be significant (See
Table 9). In the first model, only baseline PSWQ scores were included, β = .79, t(66) =
10.80, p < .001. Baseline PSWQ scores accounted for a significant amount of the variance in
week 12 scores, R2 = .65, F(1,64) = 116.70, p < .01. The ―Anxious Mood‖ nor the ―Tension‖
items of the SIGH-A at baseline were added to the second model, but this equation did not
account for a significant amount of variance beyond that accounted for by baseline PSWQ
scores.
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There were also two models shown to predict week 12 SF-36 MC scores. The first model
only included baseline SF-36 MC scores, and it was significant, β = .52, t(66) = 4.96, p < .001.
Baseline SF-36 MC scores predicted 28% of the variance in week 12 scores, ΔR2 = .28, F(1,64)
= 24.61, p < .001. In the second model, the ―Anxious Mood‖ and ―Tension‖ items were added,
but they did not account for a significant amount of variance beyond baseline scores.
A regression analysis was also conducted to see which variables predicted week 12 SF36 PC scores. Again, two models were computed. In the first model, only SF-36 PC scores were
added, β = .79, t(66) = 10.31, p < .001. Baseline SF-36 PC scores accounted for 62% of the
variance in week 12 scores, R2 = .62, F(1,64) = 106.38, p < .001. In the second model, but the
―Anxious Mood‖ and ―Tension‖ SIGH-A items were added to the equation, but they did not
account for significant variance beyond the baseline levels.
Two models were tested for their ability to predict week 12 AUC measurements of
salivary cortisol, but neither was significant. The first model only included baseline levels of
AUC, β = .30, t(66) = 1.39, p =.18. Baseline AUC measurements accounted for 9% of the
variance in week 12 scores, R2 = .09, F(1,64) = 1.94, p = .18. The second model included the
―Anxious Mood‖ and ―Tension‖ items, but still did not account for a significant amount of
vaiance, R2 = .12, F(1,64) = .85, p = .49.
Similarly, the model were tested for its ability to predict week 12 CGI-I scores, was not
significant. The ―Anxious Mood‖ and ―Tension‖ items predicted only 0.8% of the variance in
CGI-I score at week 12, R2 = .008, F(1,64) = 0.26, p = .78. Residualized change scores were
calculated for the PSWQ, the SF-36 MC and PC, and AUC for salivary cortisol as an alternative
approach to characterizing outcome. Residualized change scores are sometimes used as a way to
measure change that accounts for both the size and the reliability of the change (MacKinnon,
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2008). Using the residualized change scores as criterion variables, the ―Anxious Mood‖ and
―Tension‖ items were entered into a regression analysis using the forward entry method to
determine whether they could predict residualized change scores for the measures discussed
above. No models were significant.
Discussion
The current study aimed to determine the extent to which baseline SIGH-A symptom
clusters could predict treatment response across a variety of domains. The investigator chose to
examine the predictive value of symptoms clusters that best differentiated older adults with GAD
from those without. Though there has been debate about the ways in which anxiety differs in
older adults (Christensen et al., 1999; Spar & LaRue, 1990), in the current study, anxious mood
and tension best differentiated between groups of older adults with GAD and those without.
Older adults with GAD had higher levels of each of the symptom clusters measuring physical
symptoms of anxiety than those without GAD, but anxious mood and tension seemed to be key
symptoms for distinguishing between the two groups. These findings partially replicate the
findings by Wetherell and colleagues (2003). Wetherell and colleagues examined the diagnostic
symptoms of GAD derived from the ADIS. Using a discriminant function analysis, they found
that distress and impairment, frequency and uncontrollability of worry, muscle tension, and sleep
disturbances differentiated the groups, suggesting that they may be key symptoms of late-life
GAD. Both the current study, and the study conducted by Wetherell and colleagues found that
worry and tension differentiated between groups of older adults with GAD and those without.
However, the Wetherell study examined different characterizations of worry, specifically
frequency and uncontrollability, and distress and impairment. Moreover, they found that sleep
disturbances also differentiated between the groups. The current study derived symptom clusters
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for the analysis from the SIGH-A, while Wetherell and colleagues derived symptom clusters
from the ADIS. Though there is some overlap in the construct measured, the manner in which
the questions were asked, and the range of symptoms measured differed between the current
study and the study conducted by Wetherell and colleagues. The SIGH-A covers a broader range
of symptoms, including both diagnostic criteria, and other common anxiety symptoms. These
differences in measurement could account for the partial differences in results.
The results of the discriminant function analysis support the idea that worry and tension
are the hallmark symptoms of GAD in older adults. Moreover, the finding that ―Anxious Mood‖
and ―Tension‖ were best able to classify older adults with GAD falls into line with the proposed
DSM-V criteria for GAD, which proposes that we put more emphasis of excessive worry and
tension for the diagnosis of GAD (APA, 2010). Considering the conflicting findings in the
literature as to whether older adults present with more somatic symptoms, this shift could
simplify diagnosis of GAD in older adults.
The finding that week 12 PSWQ scores, which reflect worry, were significantly
correlated with global improvement and both physical and mental components of a measure of
quality of life, provides further support for a greater focus on worry and tension for assessing
GAD. Week 12 PSWQ scores were significantly correlated with all outcome measures except
salivary cortisol, adding support for convergent validity, and indicating the the PSWQ may be a
good measure of GAD in older adults.
Previous researchers have found significant correlations between severity of GAD as
measured by the PSWQ, and the GADSS to be positively correlated with levels of salivary
cortisol (Mantella et al., 2008). It is unclear why the levels of salivary cortisol were not
significantly correlated with any other outcome measure in this sample. It is also unclear why
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the model used to predict week 12 levels of salivary cortisol was non-significant. It is possible
that those who collected samples of salivary cortisol were qualitatively different than those who
did not, though t-tests revealed that the group that collected both baseline and week 12 samples
of salivary cortisol did not differ significantly according to age, sex, race, or years of education.
However, because only a subsample of older adults collected salivary cortisol, the current study
did not have enough power to test this outcome measure.
Contrary to our predictions, scores on the ―Anxious Mood‖ and ―Tension‖ items of the
SIGH-A at baseline did not significantly predict outcome in any domain. Ratings of baseline
levels of anxious mood or somatic tension did not significantly predict scores on outcome
measures across different domains of response. It is possible that the ―Anxious Mood‖ and
―Tension‖ items measured constructs that are semantically similar to the outcome variables. The
―Anxious Mood‖ items assess for frequency, severity, and impairment as a result of anxiety or
worry in the past week. There could be overlap in the construct that the ―Anxious Mood‖ item
and the PSWQ scale measured, as evidenced by the significant correlation between them. The
SF-36 MC and the ―Anxious Mood‖ and ―Tension‖ items were also correlated, indicating that
the constructs measured may overlap. As a result, it is possible that the SIGH-A items scores did
not account for a significant amount of variance beyond baseline measures, because they were
measuring similar things.
Moreover, it is also possible that the fact that all participants met SCID criteria for GAD
may have narrowed the range of presenting symptoms at baseline, and the severity of symptoms
at baseline. In order to meet diagnostic criteria for GAD, one must endorse excessive,
distressing and difficult to control worry on more days than not. All enrolled participants
endorsed this type of worry in order to be eligible for the study. Scores on the ―Anxious Mood‖
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item on the SIGH-A ranges from 0-4. However, those who meet full criteria for GAD would
likely automatically receive a score of 3 or 4 on the ―Anxious Mood‖ item because of the
frequency and level of distress required to meet diagnostic criteria. Possibly limited baseline
variability in the sample on the ―Anxious Mood‖ item could result in the lack of ability to predict
outcome on measures that have wider ranges of response.
Further, baseline and week 12 scores on outcomes measures tended to be highly
correlated (see Table 7), and thus accounted for much of the variability in outcome. However,
baseline scores on the PSWQ were very strong predictors of outcome at 12 weeks on the PSWQ.
Similarly, baseline scores on the SF-36 PC were very stong predictors of week 12 SF-36 PC
score. Baseline scores on the SF-36 MC were also strong predictors of week 12 SF-36 MC.
These findings indicate that higher scores on the PSWQ, the SF-36 PC, and the SF-36 MC at
baseline are associated with higher scores on each respective measure after 12 weeks of
pharmacotherapy. It is difficult to make direct comparisons with other studies examining
predictive value of symptoms because no other studies have used SIGH-A symptom clusters to
predict treatment outcome. However, we can draw some tentative comparisons to the literature.
The present findings may support the findings of Haby and colleagues (2006), who found that
greater severity of symptoms at baseline predicted poorer outcomes on measures of anxiety
symptoms and health related quality of life. However, they conflict with the findings of
Wetherell and colleagues (2005), who reported that greater severity of GAD, as measured by the
ADIS at baseline, predicted better outcomes on a reliable change index. This calls into question
whether results obtained through different methods of measurement, and defined in different
terms, can be generalized to the current study. The discrepancy could be due, in part, to
differences in defining ―improvement‖ across treatment studies. The current study defined
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improvement as a multifaceted change that took place across multiple domains. Improvement
can be a reduction in worry, improvement in quality of life, global improvement, or reduction in
levels of salivary cortisol. However, other treatment studies have used different definitions of
improvement. Again, because different predictors and outcome measures and were used in the
literature, comparisons to existing studies should be interpreted with caution.
Limitations
The current study was limited by the characteristics of the sample. It examined a
population of treatment-seeking older adults who enrolled in a pharmacotherapy study. It is
possible that these results may not generalize to other populations of older adults with GAD.
Moreover, the study sample may be qualitatively different as a result of the inclusion and
exclusion criteria (e.g., all those with substance abuse in the past 6 months were excluded) used
for study eligibility. Further, a smaller sample of older adults with GAD collected salivary
cortisol sample. It is possible that those who collected the samples were qualitatively different
than those who did not. The small sample size may have resulted in insufficient power, limiting
the findings.
Several methodological factors may limit the findings of the current study. This study
aimed to determine which symptoms were best at differentiating older adults with GAD from
those without GAD, and to see how those symptoms predicted response across different outcome
measures. However, in doing so, the investigators only examined the predictive value of the
symptoms that were best at differentiating older adults with GAD from those without and did not
examine the predictive value of other presenting symptoms. Though examining the symptoms
that are best at differentiating the two groups may make the results more clinically accessible, it
is possible that symptoms that were less successful at differentiating between older adults might
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be better predictors of outcome. Moreover, the predictor variables used were single item
responses, with a limited range. Because of the limitations of using a single-item predictor
variable with limited range, researchers might revisit the predictive value of anxious mood and
tension using more comprehensive measures designed to assess the constructs, rather than singleitem scores.
The current study was also limited in its ability to measure change. There has been
considerable controversy in the literature over the years regarding the most appropriate ways to
measure change (e.g., Cronbach & Furby, 1970). Rogosa, Brandt, and Zimowski (1982) outlined
some of the difficulties in measuring change. They discussed the established finding that initial
and outcome values tend to be correlated when measures are reliable. These correlations can
make assessing for clinically significant change difficult. A conservative approach to measuring
change was taken in the present study, but it may have missed clinically significant change that
was masked because of high correlations between baseline and outcome scores. Moreover,
without a control comparison, the current study could not account for the waxing and waning of
anxiety over the 12 weeks of treatment. The current study was also limited in its ability to assess
for treatment compliance. The investigators did not account for whether participants were taking
their medication as prescribed when assessing outcome.
Future Directions and Conclusions
The current study found that anxious mood and tension were the most salient symptoms
in differentiating older adults with GAD from those without. This suggests that measures used to
assess GAD in late life should focus on tension and anxious mood. The PSWQ was significantly
correlated with other measures of outcome, and seems to be an appropriate assessment of late life
GAD. These results are in line with the proposed criteria for the DSM-V. Though neither

29
baseline levels of anxious mood nor tension significantly predicted outcome in a variety of
measures, baseline scores on the PSWQ, SF-36 MC and SF-36 PC were strong predictors of
week 12 scores, with higher levels at baseline being associated with higher levels at week 12 on
all measures. Though these findings did not support our hypothesis that presenting symptoms
could predict outcome, they still inform expectations for treatment.
Based on these findings, researchers might consider using more comprehensive measures
of anxious mood and tension to examine their predictive value on outcome. Researchers might
also explore the predictive ability of other symptom presentations, including the other 12
symptom clusters from the SIGH-A.
Further, it would be interesting to examine longer-term outcomes. Do certain symptoms,
or baseline severity measures, predict stable improvement? Do other symptoms or severity
measures predict relapse? By learning the answers to these questions, providers could tailor
treatments for GAD to individuals who are likely to receive the most benefit.

30

References
American Psychological Association (1994). Diagnostic and Statistical Manual of Mental
Disorders, DSM-IV-TR (Fourth ed.). Washington, DC: American Psychiatric Association
(APA).
American Psychological Association (2010). DSM-5 development. Retrieved March 15, 2010
from http://www.dsm5.org/Pages/Default.aspx
Ayers, C. R., Sorrell, J. T., Thorp, S. R. & Wetherell, J. L. (2007). Evidence-based psychological
treatments for late-life anxiety. Psychology and Aging, 22(1), 8-17.
Barlow, D. H. (1981). On the relation of clinical research to clinical practice: Current issues, new
directions. Journal of Consulting, 49, 147-155.
Beaudreau, S. & O’Hara, R. (2008). Late life anxiety and cognitive impairment: A review.
American Journal of Geriatric Psychiatry, 16, 790-803.
Beck, J. G., Stanley, M. A., & Zebb, B. J. (1999). Effectiveness of the Hamilton Anxiety Rating
Scale with older generalized anxiety disorder patients. Journal of Clinical
Geropsychology, 5, 281-290.
Beekman A. T., Bremmer, M. A., Deeg, D. J., van Balkom, A. J., Smit, J. H., de Beurs, E., Van
Dyke, R., & van Tilburg, W. (1998). Anxiety disorders in later life: a report from the
longitudinal aging study Amsterdam. International Journal of Geriatric Psychiatry, 13,
717- 726.
Berk, M., Ng, F., Dodd, S., Callaly, T., Campbell, S., Bernardo, M., & Trauer, T. (2008). The
validity of the CGI severity and improvement scales as measures of clinical effectiveness
suitable for routine clinical use. Journal of Evaluation in Clinical Practice, 14, 979-983.

31
Bourland, S. L., Stanley, M. A., Snyder, A. G., et al. (2000). Quality of life in older adults with
generalized anxiety disorder. Aging and Mental Health, 4, 315–23.
Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T., &
Westlake, L. (1992). Validating the SF-36 health survey questionnaire: New outcome
measure for primary care. British Medical Journal, 305, 160-164.
Brenes, G. A., Guralnik, J. M., Williamson, J., Fried, L. P., Simpson, C., Simonsick, E. M., &
Pennix, B. W. J. H. (2005). The influence of anxiety in the progression of disability.
Journal of the American Geriatrics Society, 53, 34–39.
Brown, B. A, & Barlow, D. H. (2009). A proposal for a dimensional classification system based
on the shared features of the DSM-IV anxiety and mood disorders: Implications for
assessment and treatment. Psychological Assessment, 21, 256-271.
Chaudieu, I., Beluche, I., Norton, J., Boulenger, J. P., Ritchie, K., & Ancelin, M. L. (2008).
Abnormal reactions to environmental stress in elderly persons with anxiety disorders:
Evidence from a population study of diurnal cortisol changes, Journal of Affective
Disorders, 106, 307–313.
Christensen, H., Jorm, A. F., Mackinnon, A. J., Korten, A. E., Jacomb, P. A., Henderson, A. S., &
Rodgers, B. (1999). Age differences in depression and anxiety symptoms: A structural
equation modeling analysis of data from a general population sample. Psychological
Medicine, 29, 325-339.
Cronbach, L. J., & Furby, L. (1970). How should we measure ―change‖- or should we?.
Psychological Bulletin, 74, 68-80.

32
de Beurs, E., Beekman, A. T., van Balkom, A. J., Deeg, D. J., van Dyck, R., & van Tilburg, W.
(1999). Consequences of anxiety in older persons: Its effect on disability, well-being and
use of health services. Psychological Medicine, 29(3), 583-93.
DeMartinis, N., Rynn, M., Rickels, K., & Mandos, L. (2000). Prior benzodiazepine use and
buspirone response in the treatment of generalized anxiety disorder. Journal of Clinical
Psychiatry, 61, 91-94.
Durham, R. C., Allan, T., & Hackett, C. A. (1997). On predicting improvement and relapse in
generalized anxiety disorder following psychotherapy. British Journal of Clinical
Psychology, 36(1), 101-119.
Eid, M., & Diener, E. (Eds.) (2006). Handbook of multimethod measurement in psychology.
Washington, DC: American Psychological Association.
Ferrari, E., Magri, F., Dori, D., Migliorati, G., Nescis, T., Molla, G., Fioravanti, M., & Bruno
Solerte, S. (1995). Neuroendocrine correlates of the aging brain in humans,
Neuroendocrinology, 61, 464–470.
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (2002). Structured Clinical
Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition.
(SCID-I/NP) New York: Biometrics Research, New York State Psychiatric Institute.
Glasgow, R. E., Magid, D. J., Beck, A., Ritzwoller, D., & Estabrooks, P. (2005). Practical clinical
trials for translating research to practice: Design and measurement recommendations.
Medical Care, 43, 551-557.
Glass, C. R., & Arnkoff, D. B. (1989). Behavioral assessment of social anxiety and social phobia.
Clinical Psychology Review, 9, 75-90.

33
Goodman, W. K., Bose, A., & Wang, Q. (2005). Treatment of generalized anxiety disorder with
escitalopram: Pooled results from double—blind placebo controlled studies. Journal of
Affective Disorders, 87, 161-167.
Guy, W. (1976). NCDEU Assessment Manual for Psychopharmacology, rev. edn. US
Department of Health, Education, and Welfare (ADM) 76-338. Rockville, MD. National
Institute of Mental Health, pp. 218–222.
Haby, M. M., Donnelly, M., Corry, J., & Vos, T. (2006). Cognitive behavioural therapy for
depression, panic disorder and generalized anxiety disorder: a meta-regression of factors
that may predict outcome. Australian and New Zealand Journal of Psychiatry, 40, 9-19.
Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical
Psychology, 32, 50–55.
Hansen, A. M., Garde, A. H., & Persson, R. (2008). Sources of biological and methodological
variation in salivary cortisol and their impact on measurement among healthy adults: A
review. The Scandinavian Journal of Clinical & Laboratory Investigation, 68, 448-458.
Harman, J. S., Rollman, B. L., Hanusa, B. H., Lenze, E. J., & Shear, M. K. (2002). Physician
office visits of adults for anxiety disorders in the United States: 1985-1998. Journal of
General Internal Medicine, 17, 165-172.
Hayes, S. & O’Brien, W. H. (Eds.)(2000). Principles and practice of behavioral assessment,
New York, NY: Plenum Publishing Corporation.
Katz, I. R., Reynolds, C. F. III, Alexopoulos, G. S., & Hackett, D. (2002). Venlafaxine ER as a
treatment for generalized anxiety disorder in older adults: Pooled analysis of five
randomized placebo-controlled clinical trials. Journal of the American Geriatric Society,
50, 18-25.

34
Lacey, J. I., Bateman, D. E., & Van Lehn, R. (1953). Autonomic response specificity.
Psychosomatic Medicine, 15, 8-21.
Lang, P. J. (1968). Fear reduction and fear behavior: Problems in treating a construct. In Shlein
(Ed.), Research in Psychotherapy (pp. 90- 102). Washington, DC: American
Psychological Association.
Lecrubier, Y., Dolberg, O. T., Anderson, H. F., & Weiller, E. (2008). Qualitative changes in
symptomatology as an effect of treatment with escitalopram in generalized anxiety
disorder and major depressive disorder. European Archives of Psychiatry and Clinical
Neuroscience, 258, 171-178.
Lenze, E. J., Mulsant, B. H., Shear, M. K., Dew, M. A., Miller, M. D., Pollock, B. G., Houck, P.,
Tracey, B., & Reynolds, C. F. (2005). Efficacy and tolerability of citalopram in the
treatment of late-life anxiety disorders: Results from an 8-week randomized, placebocontrolled trial. American Journal of Psychiatry, 162, 146-150.
Lenze, E. J., Mulsant, B. H., Shear, M. K., Schulberg, H. C., Dew, M. A., Begley, A., Pollock, B.
G., & Reynolds, C. F. III (2000). Comorbid anxiety disorders in depressed elderly
patients. American Journal of Psychiatry, 157, 722-728.
Lenze, E. J., Rogers, J. C., Martire, L. M., Mulsant, B. H., Rollman, B. L., Dew, M. A., Schulz,
R., & Reynolds, C. F. (2001). The association of late-life depression and anxiety with
physical disability: A review of the literature and prospectus for future research.
American Journal of Geriatric Psychiatry, 9, 113-135.
Lenze, E. J., Rollman, B. L., Shear, M. K., Dew, M. A., Pollock, B. G., Ciliberti, C., Costantino,
M, Snyder, S., Shi, P., Spitznagel, E., Andreescu, C., Butters, M. A., & Reynolds, C. F.

35
(2009). Escitalopram for older adults with generalized anxiety disorder. Journal of the
American Medical Association, 301, 295-303.
Luz, C., Dornelles, F., Preissler,T., Collaziol, D., da Cruz, I.M., & Bauer, M. E. (2003). Impact of
psychological and endocrine factors on cytokine production of healthy elderly people.
Mechanisms of Aging and Development, 124, 887-895.
MacKinnon, D.P. (2008). Introduction to statistical mediation analysis, New York, NY: Taylor
and Francis Group.
Mantella, R. C., Butters, M. A., Amico, J. A., Mazumdar, S., Rollman, B. L., Begley, A.,
Reynolds, C. F., & Lenze, E. J. (2008). Salivary cortisol is associated with diagnosis and
severity of late-life generalized anxiety disorder. Psychoneuroendocrinology, 33, 773781.
Meyer, T. J., Miller, M. L., Metzger, R. L., & Borkovec, T. D. (1990). Development and
validation of the Penn State Worry Questionnaire. Behavior Research and Therapy, 28,
487-495.
Mohlman, J., Gorenstein, E. E., Kleber, M., de Jesus, M., Gorman, J. M., & Papp, L. A. (2003).
Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety
disorder: Two pilot investigations. American Journal of Geriatric Psychiatry, 11, 24-32.
Palmer, B. W., Jeste, D. V., & Sheikh, J. I. (1997). Anxiety disorders in the elderly: DSM-IV and
other barriers to diagnosis and treatment. Journal of Affective Disorders. 46, 183-190.
Pollack, M. H., Meoni, P., Otto, M. W., & Hackett, D. (2003). Predictors of outcome following
venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: A
pooled analysis of short- and long- term studies. Journal of Clinical
Psychopharmacology, 23, 250-259.

36
Porensky, E. K., Dew, M. A., Karp, J. F., Skidmore, E., Rollman, B. L., Shear, M. K., & Lenze,
E. J. (2009). The burden of late-life generalized anxiety disorder: Effects on disability,
health-related quality of life, and healthcare utilization. American Journal of Geriatric
Psychiatry, 17, 473-482.
Pruessner, J. C., Wolf, O. T., Hellhammer, D. H., Buske-Kirschbaum, A., von Auer, K., Jobst,
S., Kaspers, F., & Kirschbaum, C. (1997). Free cortisol levels after awakening: A reliable
biological marker for the assessment of adrenocortical activity, Life Science, 61, 2539–
2549.
Rogosa, D., Brandt, D., & Zimowski, M. (1982). A growth curve approach to measurement of
change. Quantitative Methods in Psychology, 92, 726-748.
Ryff, C. D., Love, G. D., Urry, H. L., Muller, D., Rosenkranz, M. A., Friedman, E. M., Davidson,
R. J., & Singer, B. (2006). Psychological well-being and ill-being: Do they have distinct
or mirrored biological correlates?. Psychotherapy and Psychosomatics, 75, 85-95.
Rynn, M., Khalid-Khan, S., Garcia-Espana, J. F., Etmad, B., & Rickels, K. (2006). Early
response and 8-week treatment outcome in GAD. Depression and Anxiety, 23, 461-65.
Seivewright, H., Tyrer, P., & Johnson, T. (1998). Prediction of outcome in neurotic disorder: A 5year prospective study. Psychological Medicine, 28, 1149-1157.
Shapiro, A. M., Roberts, J. E., & Beck, J. G. (1999). Differentiating symptoms of anxiety and
depression in older adults: Distinct cognitive and affective profiles?. Cognitive Therapy
and Research, 23, 53-74.
Shear, M.K., Belnap, B.H., Mazumdar, S., Houck, P., & Rollman, B.L. (2006). Generalized
Anxiety Disorder Severity Scale (GADSS): A preliminary validation study. Depression
and Anxiety, 23, 77-82.

37
Shear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H.,
Chandler, L., Williams, J., Ali, A., & Frank, D. M. (2001). Reliability and validity of a
structured interview guide for the Hamilton Anxiety rating scale (SIGH-A). Depression
and Anxiety, 13, 166-178.
Sheikh, J. I. & Cassidy, E. L. (2000). Treatment of anxiety disorders in the elderly: Issues and
strategies. Journal of Anxiety Disorders, 14, 173-190.
Spar, J. E. & LaRue, A., (1990). Geriatric Psychiatry, American Psychiatric Press, Washington,
D.C.Spielberger, C., Gorsuch, R. & Lushene, R. (1970). Manual for the State-Trait
Anxiety Inventory Consulting Psychologists Press, Palo Alto, CA.
Stanley, M. A., Beck, J. G., & Glassco, J. D. (1996). Treatment of generalized anxiety in older
adults: A preliminary comparison of cognitive-behavioral and supportive approaches.
Behavior Therapy, 27(4), 565-581.
Stanley, M. A., Diefenbach, G. J. & Hopko, D. R. (2003). The nature of generalized anxiety in
older primary care patients: Preliminary findings. Journal of Psychopathology and
Behavioral Assessment, 25(4), 273-280.
Stanley, M., Novy, D., Bourland, S., Beck, J., & Averill, P. (2001). Assessing older adults with
generalized anxiety: A replication and extension. Behaviour Research and Therapy,
39(2), 221-235.
Stein, D. J., Anderson, H. F., & Goodman, W. K. (2005). Escitalopram for the treatment of GAD:
Efficacy across different subgroups and outcomes. Annals of Clinical Psychiatry, 17(2),
71-75.

38
Tunis, S. R., Stryer, D. B., & Clancy, C. M. (2003). Increasing the value of clinical research for
decision making in clinical and health policy. Journal of the American Medical
Association, 290, 1624-1632.
Tweed, D., Blazer, D., & Ciarlo, J. (1992). Psychiatric epidemiology in elderly populations. In
R.B. Wallace & R.F. Woolson (Eds.) The Epidemiologic Study of the Elderly (pp. 213233). New York, NY: Oxford University Press
Van Cauter, E., Leproult, R., & Kupfer, D. J. (1996). Effects of gender and age on the circadian
rhythmicity of plasma cortisol. Journal of Clinical Endocrinology & Metabolism, 81,
2468-2473.
Ware, J. E. & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I.
conceptual framework and item selection. Medical Care, 30(6), 473-483.
Wetherell, J. L., Hopko, D. R., Diefenbach, G. J., Averill, P. M., Beck, J. G., Craske, M. G., et al.
(2005). Cognitive-behavioral therapy for late life generalized anxiety disorder: Who gets
better?. Behavior Therapy, 36, 147-156.
Wetherell, J. L., Le Roux, H., & Gatz, M. (2003). DSM-IV criteria for generalized anxiety
disorder in older adults: Distinguishing the worried from the well. Psychology and Aging,
18(3), 622-627.
Wetherell, J. L., Thorp, S. R., Patterson, T. L., Golshan, S., Jeste, D. V., & Gatz, M. (2004).
Quality of life in geriatric generalized anxiety disorder: A preliminary investigation.
Journal of Psychiatric Research, 38, 305-312.

39
Wisocki, P. A., Handen, B. & Morse, C. K. (1986). The Worry Scale as a measure of anxiety
among homebound and community active elderly. The Behavior Therapist, 5, 91–95.
Wittchen, H. U., Kessler, R.C., Beesdo, K., Krause, P., Höfler, M., & Hoyer, J. (2002).
Generalized anxiety and depression in primary care: prevalence, recognition, and
management. Journal of Clinical Psychiatry, 63(8), 24-34.
Zaider, T. I., Heimberg, R. G., Fresco, M., Scneier, F. R., & Liebowitz, M. R. (2003). Evaluation
of the Clinical Global Impression Scale among individuals with social anxiety disorder.
Psychological Medicine, 33, 611-622.

40
Table 1
Predictor Variables and Treatment Outcome Measures for Pharmacological Interventions
Researchers

N

Predictors

Non Predictors

Outcome
Variable(s)

Pollack et al.,
2003

N=1,839
(pooled data)

Sleep disturbance
predicted positive
outcomes in both
active treatment and
placebo groups.
Restlessness
predicted poorer
outcomes for both
groups. Trouble
concentrating and
history of substance
abuse predicted
better short-term
outcomes for
placebo group

Reduction in
HAM-A

DeMartinis,
Rynn, Rickels, &
Mandos, 2000

N= 735

Poorer prognosis
associated with
recent
benzodiazepine use

Age, duration
of episode,
benzodiazepine
use, history of
depression,
history of
panic disorder,
fatigability,
irritability,
muscle
tension, and
number of
GAD
diagnostic
criteria
endorsed
Prior
benzodiazepine
use, no
benzodiazepine
use

Rynn, KhalidN=396
Khan, GarciaEspana, Estemad,
& Rickels, 2006

Better outcomes
***
were associated
with early reduction
in HAMA (baseline
to weeks 1 and 2)

Reduction in
HAM-A
CGI
Patient attrition
Reduction in
HAM-A at the
end of the trial
CGI
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Table 2
Predictor Variables and Treatment Outcome Measures for Psychosocial Interventions
Researchers

N

Predictors

Non Predictors

Outcome
Variable(s)

Seivewright,
Tyrer, &
Johnson, 1998

210
Poorer prognosis
psychiatric predicted by older
outpatients age, presence of
personality
disorder at
baseline, and the
presence of a
general neurotic
syndrome at
baseline

Sex, marital status,
Health service
social class, treatment utilization
randomization group,
DSM-III diagnosis at
baseline, duration of
symptoms, single or
recurrent episodes,
life stress, baseline
total scores on a
measure of general
psychopathology,
depression scores,
anxiety scores,
number of comorbid
symptoms

Haby,
Donnelly,
Corry & Vos,
2006

Pooled
data

Poorer outcomes
were associated
with inclusion of
greater severity at
baseline, presence
of a waitlist
control group
instead of an
attention control.

Treatment type, year
of study, length of
trial, country of
study, language and
number of dropouts
from the control
group

Symptom
levels,
Functioning
Health-related
quality of life
measures

Durham,
Allan, &
Hackett, 1997

N=80

Being married
was associated
with better
outcomes, and
marital tension
predicted poorer
outcomes.
Presence of other
Axis I diagnoses
predicted poorer
outcomes.

Screening variables,
referral variables

Sustained
improvement,
relapse and no
consistent
change

42
Wetherell et
al., 2005

N= 65

Better outcomes
were associated
with higher GAD
severity at
baseline, presence
of Axis I
comorbidity, and
more frequent
homework

Age, gender,
ethnicity, education,
work status, duration
of episode, sessions
attended

Reliable
change indices
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Table 3
Demographic and Participant Characteristics by Diagnosis
GAD (N = 177)

Control (N= 41)

71.58

75.12

7.74

6.26

60 - 89

62-88

Male (%)

32.3

33.3

Female (%)

66.1

66.7

13.86

14.48

SD

2.90

2.87

Range

2-20

7-20

Age
Mean
SD
Range
Gender

Education (years)
Mean

Marital
Never Married (%)

9.4

7.9

Married (%)

52.6

68.4

Separated

1.8

2.6

Divorced (%)

12.3

7.9

Widowed (%)

22.8

13.2

Cohabitating (%)

1.2

0.0
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Table 3 (continued)
Ethnicity
Caucasian (%)

81.9

92.9

African American (%)

17.5

7.1

Asian Pacific (%)

0.6

0.0

Disabled (%)

5.3

0.0

Working Full Time (%)

7.6

2.6

Working Part Time (%)

9.4

5.3

Homemaker (%)

8.2

5.3

Unemployed (%)

6.4

0.0

63.2

86.8

Job Status

Retired (%)
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Table 4
Means for Outcome Measures for all participants with GAD at Baseline
GAD
Measure

M

SD

PSWQ

51.86

15.96

SF-36 MC

44.89

10.86

SF-36 PC

42.65

10.64

Salivary Cortisol (AUC)

29.25

10.69
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Table 5
Group differences for outcome measures at baseline and week 12 for participants with GAD who
were randomized to medication
Baseline scores
Outcome measure

Week 12 scores

M

SD

M

SD

t (138)

PSWQ

54.29

12.46

47.76

12.30

.001**

SF-36 MC

42.24

8.89

47.29

8.74

.001**

SF-36 PC

39.72

11.16

39.85

11.48

.89

Salivary cortisol (AUC)

29.43

10.91

25.72

12.79

.23
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Table 6
Correlations Between Baseline and Week 12 Administration of Predictor and Outcome Measures
Measure

1

1. PSWQ
Baseline

--

2. PSWQ
Week 12

.80**

--

-.43**

-.52** --

-.16

-.45

.52** --

.29*

-.27

-.08

--

.18

.28*

-.22

-.15

.79**

--

.32

.20

-.16

-.16

.26

.17

--

.14

.19

-.25

-.15

.22

.03

.30

--

9. CGI-I
Week 12

.15

.39**

-.15

-.46**

-.19

-.23

.19

.19

--

10.

.32**

.24*

-.19

-.30*

.01

.11

-.19

.12

-.05

3. SF-36
MC
Baseline
4. SF-36
MC
Week 12
5. SF-36
PC
Baseline
6. SF-36
PC
Week 12
7.
Salivary
Cortisol
AUC
Baseline
8.
Salivary
Cortisol
AUC
Week 12

.13

2

3

4

5

6

7

8

9

10

11

48
―Anxious
Mood‖
item
Baseline
11.
―Tension‖
.07
item
Week 12
*p<.01. ** p<.001.

--

.04

-.24*

-.07

-.12

-.17

.04

-.03

-.05

.02 --
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Table 7
Differences Between SIGH-A Cluster Item Scores in the GAD and Control Group
GAD

No GAD

(n = 177)

(n = 41)

Symptom Cluster

M

SD

M

SD

t (216)

1. Anxious Mood

3.01

.34

.34

.53

40.65**

2. Tension

2.70

.58

.29

.56

24.20**

3. Fears

.59

.87

.02

.16

4.15**

4. Insomnia

2.76

.84

.98

1.06

11.62**

5. Concentration

1.77

.93

.49

.64

8.42**

6. Depressed

1.34

.92

0.00

0.00

9.41**

2.28

.98

.73

1.00

9.09**

1.49

1.12

.46

.64

6.19**

9. Cardiovascular

.60

.86

.15

.48

3.27**

10. Respiratory

1.19

.96

.10

.30

7.24**

11. Gastro-

1.80

1.04

.68

.85

6.43**

Mood
7. Somatic
Muscular
8. Somatic
Sensory

intestinal
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12. Genito-

.91

1.14

.32

.88

3.12*

13. Autonomic

1.13

.99

.15

.48

6.21**

14. Interview

1.41

.65

.08

.27

12.71**

urinary

Behavior
*p<.01. ** p<.001.
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Table 8
Classification Results for Discriminant Function Analysis
Predicted group membership
GAD
No GAD
Actual Group Membership
n
n
%
n
%
GAD
41
41
100.0
0
0.0
No GAD
177
0
0.0
177
100.0
Note. Overall percentage of correctly classified cases = 100.0%
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Table 9
Regression Models for Predicting Outcomes of GAD Using SIGH-A Clusters as Predictors
Variable

B

SEB

β

PSWQ
Model 1
Baseline PSWQ

.79

.07

.80**

.78
2.36
-.83

.08
4.58
1.81

.79
.04
-.03

Model 2
Baseline PSWQ
Baseline ―Anxious Mood‖
Baseline ―Tension‖
SF-36 MC
Model 1
Baseline SF-36 MC
Model 2
Baseline SF-36 MC
Baseline ―Anxious Mood‖
Baseline ―Tension‖
SF-36PC
Model 1
Baseline SF-36 PC
Model 2
Baseline SF-36 PC
Baseline ―Anxious Mood‖
Baseline ―Tension‖
CGI-I
Model 1
Baseline ―Anxious Mood‖
Baseline ―Tension‖
Salivary Cortisol AUC
Model 1
Baseline AUC
Model 2
Baseline PSWQ
Baseline ―Anxious Mood‖
Baseline ―Tension‖
*p<.01. ** p<.001.

.52

.10

.52**

.50
-6.24
.91

.11
4.41
1.87

.51**
-.15
.05

.81

.08

.79**

.80
5.58
-1.63
-.17
.13

.35
.39
11.30
-1.18

.08
4.11
1.73
.41
.22

.25
.26
13.57
4.50

.78**
.10
-.07
-.05
.07

.30
.34
.19
-.06

R2

ΔR2

.65**

.65**

.65**

.003

.28**

.28**

.30**

.03

.62**

.62**

.64**

.02

.008

.008

.09

.09

.12

.04
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Appendix A
Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A)
The purpose of this interview guide is to assist in the reliable assessment of anxiety
severity by standardizing the method of assessment and providing clear anchor points for the
assignment of severity ratings. The interview items and the anchor points are meant to
supplement good clinical judgment, not replace it. To ensure full assessment of the domain of
inquiry for each item, the interviewer should ask all questions provided. These defining
characteristics are meant to aid in the reliable use of the severity scales; they represent examples
of the severity levels appropriate to the rating, Severity is defined most readily the frequency of
occurrence, degree of distress and interference associated with the symptom. The number of
symptoms present is included in the severity rating only as it impacts on distress and
interference. For example, a higher rating may be achieved for a single severe symptom and for
several mild to moderate symptoms. Alternatively, several mild symptoms may lead to a
moderate rating of severity because of their overall impact on distress.
In addition to the guidelines for each item, the interviewer should note the following
conventions for boundary problems:
A. None to mild boundary: Most questionable cases should be rated as one, as zero is
meant to be an anchor point with no symptoms present.
B. Mild to moderate boundary: Symptoms are endorsed less than fifty percent of the
time and cause little or no interference or distress; rate as one. Symptoms are
endorsed less than fifty percent of the time and are rated as causing mild to moderate
interference or distress; rate as two. Symptoms are endorsed more than fifty percent
of the time and are rated as causing mild interference or distress; rate as two.
C. Moderate to severe boundary: Symptoms are endorsed less than fifty percent of the
time and are rated as causing severe interference or distress; rate as three. Symptoms
are endorsed more than fifty percent of the time and are rated as causing moderate to
severe interference or distress, but not both; rate as three.
D. Severe to very severe boundary: Questionable cases should generally be rated as
three, ratings of four are reserved for behavioral events clearly identified by the rating
anchors.
To elicit information necessary for assigning severity ratings, the interviewer must assess the
frequency of occurrence, degree of distress, and degree of interference associated with the
symptoms. The following questions are recommended for this assessment:
A. Have you have the symptom every day? IF NO, Have you had the symptom more
days than not?
B. How much does the symptom bother you?
C. How much does it interfere with your life?
Starting the interview: Begin the interview with an introduction, describing the scale and
its purpose in a way that is relevant for the specific patient and for the specific assessment. For
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example, for the first administration, one might say, “As you know, we have diagnosed your
condition as an anxiety disorder. We are now going to be asking you a number of questions
about different aspects of your anxiety. Together, they allow us to rate as accurately as possible
the overall severity of your anxiety state. We will be rating anxiety severity in this way at
different points in your treatment in order to decide how much the treatment is helping you.”
This example is not meant as a script. The interviewer should introduce the scale in a way most
comfortable for the patient and for her/his own style.
It is assumed that the interviewer has completed a previous diagnostic interview and is
familiar with the patient’s general range of symptoms. If this is not true, the interviewer should
preface the Hamilton Anxiety Scale by asking for a summary (five or ten minutes) of the
patient’s specific worries, disturbing physical symptoms, duration of the syndrome, and its
characteristics over time (e.g. Does it tend to wax and wane, or has it been persistent since the
onset?). The interviewer should also obtain a global statement on distress and impairment during
the last week, and the cause of this distress. This information will provide the rater with a
background or framework from which to conduct the ratings.
Although there are differences between studies, it is assumed that all ratings for the
Hamilton Anxiety Rating Scale for patients with panic disorder will focus exclusively on times
other than panic episodes.
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1. Anxious Mood
What’s your mood been like this
week?
Have you been feeling anxious?
Nervous?
Worrying?
Feeling something bad may happen?
Feeling irritable?

0- No anxious mood
1- Mild worry or anxiety indicated only on
questioning; no change in functioning
2- Preoccupation with minor events, anxiety
on as many days as not
3- Nearly daily episodes of anxiety/ worry with
disruption of daily activities; daily
preoccupation
4- Nearly constant anxiety; significant role
disruption

2. Tension
Have you been feeling tense?
Do you startle easily?
Cry easily?
Fatigue easily?
Have you been trembling?
Feeling restless?
Unable to relax?

0- No tension
1- Several days of mild tension or occasional
(e.g., 1-2) episodes of exaggerated startle or
labile mood
2- Muscle tension or fatigue 50% of the time
or repeated (>2) episodes of trembling,
exaggerated startle, etc.
3- Nearly daily muscle tension, fatigue and/or
restlessness >75% of the time or persistent,
disruptive symptoms
4- Constant tension, restlessness, agitation,
unable to relax in the interview
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3. Fears
Have you been feeling fearful
(phobic) of situations or events?
For example, have you been
afraid of the dark?
Of strangers?
Of being left alone?
Of animals?
Of being caught in traffic?
Of crowds?
Other fears?

0- No fears
1- Mild phobic concerns that do not cause
significant distress or disrupt functioning
2- Fears lead to distress or avoidance on one or
more occasions
3- Fears are an object of concern on a near
daily basis (75%); patient may need to be
accompanied by others to a fearful event
4- Fears or avoidance that markedly affect
function. Patient may avoid multiple
situations even if accompanied; extensive
agoraphobia

4. Insomnia
How have you been sleeping this
past week?
Any difficulties falling asleep?
Any problems with waking
during the night?
Waking early and not being able
to return to sleep?
Do you feel rested in the
morning?

0- No sleep disturbance
1- Mildly disrupted sleep (e.g., one or two
nights of difficulties falling asleep or
nightmares)
2- Several episodes of sleep disturbance that is
regular but not persistent (e.g., over onehalf hour falling asleep, nightmares, or
excessive AM fatigue)
3- Persistent sleep disruption (on more days
than not), characterized by difficulty falling
asleep (e.g., over one half hour) or staying
asleep, restlessness, unsatisfying sleep or
frequent nightmares, or fatigue
4- Nightly difficulties with sleep onset or
maintenance, or daily severe fatigue on
waking in the AM
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5. Concentration
Have you had trouble
concentrating?
Remembering things?

0- No difficulties
1- Infrequent episodes of forgetfulness or
difficulty concentrating that are not
distressing to the patient
2- Recurrent episodes of forgetfulness or
difficulty concentrating, or episodes of
sufficient intensity to cause the patient
recurrent concern
3- Persistent concentration or memory
impairment that interferes with daily tasks
4- Significant role impairment due to
concentration difficulties

6. Depressed Mood
Have you been feeling depressed?
Have you lost interest in things?
Do you get pleasure from friends
or hobbies?

0- No depression
1- Occasional or mild blue or sad mood, or
reports of decreased enjoyment of activities
2- Sad or blue mood or disinterest 50% of the
time, mood does not generally interfere with
functioning
3- Persistent depressed mood or loss of
pleasure, mood is significantly distressing to
patient, or may be evident to others
4- Daily evidence of severe depression with
significant role impairment
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7. Somatic Muscular
Have you been experiencing any
aches, pains, or stiffness in your
muscles?
Have you experienced any muscle
twitching or sudden muscle jerks?
Have you had an unsteady voice?

0- No muscular symptoms
1- Infrequent presence of one or two
symptoms, no significant distress
2- Mild distress over several
symptoms or moderate distress over a single
symptom
3- Symptoms occur on more days than not,
symptoms are associated with moderate to
severe distress and/or regular attempts at
symptom control by limiting activities or
taking medications
4- Daily or near daily episodes of symptoms
that cause the patient significant distress and
lead to restriction of activities or repeated
visits for medical attention

8. Somatic Sensory
Have you been experiencing any
ringing in your ears?
Blurred vision?
Hot or cold flashed?
Feelings of weakness?
Or prickling sensations?

0- No symptoms
1- Infrequent presence of one or two
symptoms, no significant distress
2- Mild distress over several symptoms or
moderate distress over a single symptom
3- Symptoms occur on more days than not,
symptoms are associated with moderate to
severe distress and/or regular attempts at
symptom control by limiting activities or
taking medications
4- Daily or near daily episodes of symptoms
that cause the patient significant distress and
lead to restriction of activities or repeated
visits for medical attention
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9. Cardiovascular
Have you had episodes of a
racing, skipping, or pounding
heart?
How about pain in your chest?
Fainting feelings?

0- No symptoms
1- Infrequent presence of one or two
symptoms, no significant distress
2- Mild distress over several symptoms or
moderate distress over a single symptom
3- Symptoms occur on more days than not,
symptoms are associated with moderate to
severe distress and/or regular attempts at
symptom control by limiting activities or
taking medications
4- Daily or near daily episodes of symptoms
that cause the patient significant distress and
lead to restriction of activities or repeated
visits for medical attention

10. Respiratory
Have you been having trouble
with your breathing?
Any pressure or constriction in
your chest?
Choking feelings?
Sighing?
or Feeling like you can’t catch
your breath?

0- No symptoms
1- Infrequent presence of one or two
symptoms, no significant distress
2- Mild distress over several symptoms or
moderate distress over a single symptom
3- Symptoms occur on more days than not,
symptoms are associated with moderate to
severe distress and/or regular attempts at
symptom control by limiting activities or
taking medications
4- Daily or near daily episodes of symptoms
that cause the patient significant distress and
lead to restriction of activities or repeated
visits for medical attention
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11. Gastro-intestinal
Have you had any stomach pain
or discomfort?
Nausea or vomiting?
Burning or rumbling in your
stomach?
Heartburn?
Loose bowels?
Constipation?
Sinking feeling in your stomach?

0- No symptoms
1- Infrequent and minor episodes of gastric
discomfort, constipation, or loosening of
bowel, fleeting nausea
2- An episode of vomiting or recurrent
episodes of abdominal pain, loosening of
bowels, difficulty swallowing, etc.
3- Symptoms more days than not that are very
bothersome to the patient or lead to
concerns over eating, bathroom availability,
or use of medication
4- Daily or near daily episodes of symptoms
that cause the patient significant distress and
lead to restriction of activities or visits for
medical attention

12. Genito-urinary
Have you been experiencing any
urinary difficulties?
For example, have you had to
urinate more frequently than
usual?
Have you had more urgency to
urinate?
Have you had decreased sexual
interest?

0- No symptoms
1- Infrequent or minor urinary symptoms or
mild changes in sexual interest
2- Urinary symptoms several days during the
week, occasional difficulties with sexual
functioning
3- Urinary or sexual symptoms more days than
not
4- Daily urinary or sexual symptoms that lead
to distress and medical care seeking
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13. Autonomic
Have you been experiencing any
flushing in your face?
Getting pale?
Lightheadedness?
Have you been having any
tension headaches?
Have you felt the hair rise on
your arms, the back of your neck
or head, as though something had
frightened you?

14. Behavior
Rate Interview Behavior
Fidgeting, restlessness or pacing,
tremor of hands, furrowed brow,
strained face, sighing or rapid
respirations, facial pallor,
frequent swallowing, etc.

0- No symptoms
1- Mild symptoms that occur infrequently
2- Symptoms occurred several times during the
week and were bothersome
3- Near daily symptoms with distress or
embarrassment about the symptoms
4- Daily symptoms that are a focus of distress
and impair function (e.g. daily headaches or
lightheadedness leading to limitation of
activities)
0- No apparent symptoms
1- Presence of one or two symptoms to a mild
degree
2- Presence of several symptoms of mild
intensity or one symptom of moderate
intensity
3- Persistent symptoms throughout the
interview
4- Agitation, hyperventilation, difficulty
completing the interview
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Appendix B
Penn State Worry Questionnaire

Enter the number that best describes how typical or characteristic each item is of you,
putting the number next to the item.
1

2

typical
Not at all

3

4

typical
Somewhat

5
typical
Very

______

1.

If I don’t have enough time to do everything, I don’t worry about it.

______

2.

My worries overwhelm me.

______

3.

I do not tend to worry about things.

______

4.

Many situations make me worry.

______

5.

I know I shouldn’t worry about things, but I just cannot help it.

______

6.

When I am under pressure I worry a lot.

______

7.

I am always worrying about something.

______

8.

I find it easy to dismiss worrisome thoughts.

______

9.

As soon as I finish one task, I start to worry about everything else I have to

do.
______

10. I never worry about anything.

______

11. When there is nothing more I can do about a concern, I don’t worry about
it anymore.

______

12. I’ve been a worrier all my life.

______

13. I notice that I have been worrying about things.

______

14. Once I start worrying, I can’t stop.

______

15. I worry all the time.

______

16. I worry about projects until they are done.
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Appendix C
SF-36
1. In general, would you say your health is:
Excellent
1

Very Good
2

Good
3

Fair
4

Poor
5

2. Compared to one year ago, how would you rate your health in general now?
Much Better
than one year
ago
1

Somewhat
better now than
one year ago
2

About the same
as one year ago
3

Somewhat
worse now than
one year ago
4

Much worse
now than one
year ago
5

3. The following items are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
a.

Vigorous activities, such as running, lifting heavy objects, participating in
strenuous sports
Yes, Limited a lot
1

Yes, Limited a little
2

No, Not Limited at all
3

b. Moderate activities, such as moving a table, pushing a vacuum cleaner,
bowling, or playing golf
Yes, Limited a lot
1

Yes, Limited a little
2

No, Not Limited at all
3

Yes, Limited a little
2

No, Not Limited at all
3

c. Lifting or carrying groceries
Yes, Limited a lot
1

d. Climbing several flights of stairs
Yes, Limited a lot
1

Yes, Limited a little
2

No, Not Limited at all
3
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e. Climbing one flight of stairs
Yes, Limited a lot
1

Yes, Limited a little
2

No, Not Limited at all
3

f. Bending, kneeling, or stooping
Yes, Limited a lot
1

Yes, Limited a little
2

No, Not Limited at all
3

Yes, Limited a little
2

No, Not Limited at all
3

Yes, Limited a little
2

No, Not Limited at all
3

Yes, Limited a little
2

No, Not Limited at all
3

Yes, Limited a little
2

No, Not Limited at all
3

g. Walking more than a mile
Yes, Limited a lot
1
h. Walking several blocks
Yes, Limited a lot
1
i. Walking one block
Yes, Limited a lot
1
j.

Bathing or dressing yourself
Yes, Limited a lot
1

4. During the past 4 weeks, have you had any of the following problems with your work
or other regular daily activities as a result of your physical health?
a.

Cut down the amount of time you spent on work or other activities.
Yes = 1

No = 0
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b. Accomplished less than you would like
Yes = 1

No = 0

c. Were limited in the kind of work or other activities
Yes = 1

No = 0

d. Had difficulty performing the work or other activities (for example, it took
extra effort)
Yes = 1

No = 0

5. During the past 4 weeks, have you had any of the following problems with your work
or other regular daily activities as a result of any emotional problems (such as feeling
depressed or anxious)?
a. Cut down the amount of time you spent on work or other activities
Yes = 1

No = 0

b. Accomplished less than you would like
Yes = 1

No = 0

c. Didn't do work or other activities as carefully as usual
Yes = 1

No = 0

6. During the past 4 weeks, to what extent has your physical health or emotional
problems interfered with your normal social activities with family, friends, neighbors, or
groups?
Not at all
0

Slightly
1

Moderately
2

Quite a bit
3

Extremely
4

7. How much bodily pain have you had during the past 4 weeks?
None
0

Very Mild
1

Mild
2

Moderate
3

Severe
4

Very Severe
5
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8. During the past 4 weeks, how much did pain interfere with your normal work
including both work outside the home and housework)?
Not at all
0

Slightly
1

Moderately
2

Quite a bit
3

Extremely
4

9. These questions are about how you feel and how things have been with you during the
past 4 weeks. For each question, please give the one answer that comes closest to the way
you have been feeling. How much of the time during the past 4 weeks:
a. Did you feel full of pep?
All of the
time
0

Most of the
time
1

Some of
the time
2

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A little of
the time
4

None of the
time
5

b. Have you been a very nervous person?
All of the
time
0
c.
All of the
time
0
d.
All of the
time
0
e.
All of the
time
0

Most of the
time
1

Some of
the time
2

A good bit
of the time
3

Have you felt so down in the dumps that nothing could cheer you up?
Most of the
time
1

Some of
the time
2

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A good bit
of the time
3

A little of
the time
4

None of the
time
5

Have you felt calm and peaceful?
Most of the
time
1

Some of
the time
2

Did you have a lot or energy?
Most of the
time
1

Some of
the time
2
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f.

Have you felt downhearted and blue?

All of the
time
0
g.

Most of the
time
1

Some of
the time
2

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A good bit
of the time
3

A little of
the time
4

None of the
time
5

A good bit
of the time
3

A little of
the time
4

None of the
time
5

Did you feel worn out?

All of the
time
0
h.

Most of the
time
1

Some of
the time
2

Have you been a happy person?

All of the
time
0
i.

Most of the
time
1

Some of
the time
2

Did you feel tired?

All of the
time
0

Most of the
time
1

Some of
the time
2

10. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting with friends, relatives, etc.)?
All of the
time
0

Most of the
time
1

Some of
the time
2

A good bit
of the time
3

A little of
the time
4

None of the
time
5

11. How TRUE or FALSE is each of the following statements for you?
a. I seem to get sick a little easier than other people
Definitely
True
0

Mostly True

Don’t know

Mostly false

1

2

3

Definitely
false
4
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b. I am as healthy as anybody I know
Definitely
True
0

Mostly True

Don’t know

Mostly false

1

2

3

Mostly True

Don’t know

Mostly false

1

2

3

Mostly True

Don’t know

Mostly false

1

2

3

Definitely
false
4

c. I expect my health to get worse
Definitely
True
0

Definitely
false
4

d. My health is excellent
Definitely
True
0

Definitely
false
4
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Appendix D
Clinical Global Impression – Global Improvement (CGI –I) Scale
Rate total improvement whether or not, in your clinical judgment, it is due entirely to
drug treatment.
Compared to baseline, how much has he/she changed?
□
□
□
□
□
□
□
□

John H.
Hagen

Digitally signed by John H.
Hagen
DN: cn=John H. Hagen,
o=West Virginia University
Libraries, ou=Acquisitions
Department, email=John.
Hagen@mail.wvu.edu, c=US
Date: 2010.06.02 13:33:40
-04'00'

0 = Not assessed
1 = Very much improved
2 = Much improved
3 = Minimally improved
4 = No change
5 = Minimally worse
6 = Much worse
7 = Very much worse

